Bioptimus 7600万美元赌注：一个基础模型覆盖全生物学，先开源

做的是什么生意

Paris-based startup training large AI foundation models on multimodal biological data — pathology slides, genomics, clinical records — to speed diagnosis and drug discovery, selling model access to pharma and researchers.

启动资金：$35M seed (Feb 2024, led by Sofinnova Partners with Bpifrance, Cathay Innovation, Xavier Niel and Owkin), then a $41M Series A (Jan 2025, led by Cathay Innovation) — $76M total.

起因

Bioptimus emerged from stealth on Feb 20, 2024 in Paris as a spin-off of Owkin, the French biotech unicorn, co-founded by Owkin's chief R&D officer Jean-Philippe Vert and ex-Google and DeepMind researchers including CTO Rodolphe Jenatton. It raised a $35M seed led by Sofinnova Partners, signed an AWS compute partnership, and set out to train a foundation model of biology on Owkin's multimodal patient data from leading academic hospitals.

经过

In July 2024, less than five months after launch, Bioptimus released H-Optimus-0, the world's largest open-source pathology foundation model — 1.1B parameters trained on 500,000+ histopathology slides — claiming state-of-the-art results on diagnostic tasks from detecting cancer cells to tumor biomarkers. In Jan 2025 it raised a $41M Series A led by Cathay Innovation (with Sofinnova, Bpifrance, Andera, Hitachi Ventures, Boom Capital, Pomifer, Sunrise and angels), bringing total funding to $76M, and said it was preparing a multimodal model spanning the entire biological spectrum.

可借鉴之处

独家多模态数据可以成为护城河：Owkin 的医院网络让一家种子轮初创公司能训练出对手无法企及的模型，而先开源第一个模型在商业推销前建立了可信度。